The estimated Net Worth of Michael P. Samar is at least $1.35 Milión dollars as of 25 July 2022. Mr Samar owns over 2,020 units of Assembly Biosciences Inc stock worth over $1,342,223 and over the last 5 years he sold ASMB stock worth over $9,443.
Mr has made over 2 trades of the Assembly Biosciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,020 units of ASMB stock worth $4,484 on 25 July 2022.
The largest trade he's ever made was selling 2,285 units of Assembly Biosciences Inc stock on 29 March 2022 worth over $4,958. On average, Mr trades about 538 units every 15 days since 2019. As of 25 July 2022 he still owns at least 77,228 units of Assembly Biosciences Inc stock.
You can see the complete history of Mr Samar stock trades at the bottom of the page.
Michael P. Samar is the CFO & Principal Accounting Officer at Assembly Biosciences Inc.
Mr Samar is 49, he's been the CFO & Principal Accounting Officer of Assembly Biosciences Inc since . There are 12 older and 5 younger executives at Assembly Biosciences Inc. The oldest executive at Assembly Biosciences Inc is Alan Lewis, 74, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCSICO, CA, 94080.
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak a Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
Assembly Biosciences Inc executives and other stock owners filed with the SEC include: